Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced the results of its annual general and special meeting of shareholders, held on September 26, 2025, in Toronto. Shareholders representing 12 Class A multiple voting shares—entitling holders to 276,660 votes per share—and 1,769,228 Class B subordinate voting shares were present in person or by proxy, accounting for 100% of Class A votes and 46.352% of Class B votes. All resolutions presented at the meeting were approved, signaling strong shareholder confidence in the company's leadership and strategic initiatives.
The approval of these resolutions is significant for Quantum BioPharma as it continues to advance its pipeline of innovative biotech solutions. The company is dedicated to building a portfolio of assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis.
In addition to its core research, Quantum BioPharma has commercialized unbuzzd(TM), an over-the-counter product aimed at alcohol misuse. The company spun out the OTC version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which is led by industry veterans. Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2025, and is entitled to royalty payments of 7% of sales from unbuzzd(TM) until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Importantly, Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The company also maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which focuses on loans secured by residential or commercial property. This diversified approach provides Quantum BioPharma with financial flexibility to support its research and development efforts.
The strong shareholder approval at the annual meeting underscores the market's confidence in Quantum BioPharma's strategy to address significant unmet medical needs. With a robust pipeline and strategic partnerships, the company is well-positioned to make advancements in the treatment of multiple sclerosis and other disorders. For more details, the full press release is available at https://ibn.fm/D5GzF. Investors can stay updated with the latest news from Quantum BioPharma at https://ibn.fm/QNTM.
